Treatment Landscape for Hepatocellular Carcinoma Evolves at Rapid Pace
Ghassan K. Abou-Alfa, MD, discusses the evolution of the treatment landscape in hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, from the Memorial Sloan Kettering Cancer Center, discusses the evolution of the treatment landscape in hepatocellular carcinoma (HCC).
The treatment landscape for HCC has evolved very rapidly, says Abou-Alfa, especially over the last few years. Treatment has been very dependent on local therapy in HCC as there was no evidence for systemic therapy enhancing survival. However, this changed markedly with the introduction of tyrosine kinase inhibitor (TKI) sorafenib (Nexavar).
Sorafenib showed an improvement in survival compared with placebo, which led to physicians becoming dependent on this TKI for close to a decade. Abou-Alfa explains. New advances have now come into play with different TKIs, as well as the promise of checkpoint inhibition, which have demonstrated promise as combination regimens.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
